1. Home
  2. CUE vs SKYE Comparison

CUE vs SKYE Comparison

Compare CUE & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUE
  • SKYE
  • Stock Information
  • Founded
  • CUE 2014
  • SKYE 2012
  • Country
  • CUE United States
  • SKYE United States
  • Employees
  • CUE N/A
  • SKYE N/A
  • Industry
  • CUE Biotechnology: Pharmaceutical Preparations
  • SKYE Biotechnology: Pharmaceutical Preparations
  • Sector
  • CUE Health Care
  • SKYE Health Care
  • Exchange
  • CUE Nasdaq
  • SKYE Nasdaq
  • Market Cap
  • CUE 48.0M
  • SKYE 73.4M
  • IPO Year
  • CUE 2018
  • SKYE N/A
  • Fundamental
  • Price
  • CUE $0.68
  • SKYE $4.61
  • Analyst Decision
  • CUE Strong Buy
  • SKYE Buy
  • Analyst Count
  • CUE 3
  • SKYE 6
  • Target Price
  • CUE $3.00
  • SKYE $16.60
  • AVG Volume (30 Days)
  • CUE 311.2K
  • SKYE 2.0M
  • Earning Date
  • CUE 08-13-2025
  • SKYE 08-08-2025
  • Dividend Yield
  • CUE N/A
  • SKYE N/A
  • EPS Growth
  • CUE N/A
  • SKYE N/A
  • EPS
  • CUE N/A
  • SKYE N/A
  • Revenue
  • CUE $7,991,000.00
  • SKYE N/A
  • Revenue This Year
  • CUE N/A
  • SKYE N/A
  • Revenue Next Year
  • CUE $23.84
  • SKYE N/A
  • P/E Ratio
  • CUE N/A
  • SKYE N/A
  • Revenue Growth
  • CUE 13.83
  • SKYE N/A
  • 52 Week Low
  • CUE $0.45
  • SKYE $1.14
  • 52 Week High
  • CUE $1.99
  • SKYE $7.60
  • Technical
  • Relative Strength Index (RSI)
  • CUE 47.91
  • SKYE 74.70
  • Support Level
  • CUE $0.65
  • SKYE $3.41
  • Resistance Level
  • CUE $0.71
  • SKYE $5.75
  • Average True Range (ATR)
  • CUE 0.08
  • SKYE 0.60
  • MACD
  • CUE 0.00
  • SKYE 0.17
  • Stochastic Oscillator
  • CUE 38.62
  • SKYE 69.27

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: